Gilead to Pay Up to $282M for Genmab HIV Platform

Source: The Country Caller

Aug 11, 2016

Gilead Sciences has been exclusively granted licensed use of Genmab’s DuoBody technology, in an aim to create a platform for the development of antibodies targeting HIV.

Gilead will pay Denmark-based Genmab $5 million upfront, followed by regulatory and sales milestone up to $277 million for the first product.

The bispecific antibody technology from Genmab uses antibodies to efficiently target disease and cease the bacterial activity. The platform will strengthen Gilead's presence in a growing field of HIV research.

Read the Country Caller Coverage